Smith & Nephew stock gains on new knee system clearance

Smith & Nephew stock is supported by a new US regulatory milestone as the company announced FDA 510(k) clearance and the first surgical cases for its LANDMARK Total Knee System on September 22, 2026. The shares closed at GBX 1,027.50 on September 18, 2026, down GBX 8.00, or 0.77 percent, on the London Stock Exchange, according to MarketBeat data.

FDA clearance adds product momentum

The LANDMARK system is designed for total knee replacement procedures, and Smith+Nephew linked the clearance with the first completed surgeries in its September 22 announcement. The company is a constituent of the FTSE 100 and trades in London under SN, while its American Depositary Shares trade under SNN in New York, according to a company release published through GlobeNewswire.

The product event matters because knee reconstruction is one of Smith & Nephew's core orthopaedics areas. It also gives the market a concrete commercial milestone alongside the company's latest reported numbers, rather than relying only on longer-term pipeline claims.

Latest figures come from first half

Smith & Nephew's investor page lists second-quarter and first-half 2026 results dated July 29, 2026. The reporting period is within the current nine-month freshness window for interim figures, although the indexed material available for this article does not provide the underlying revenue and profit values.

MarketBeat's September 18 snapshot reported a London price of GBX 1,027.50, a market capitalization of GBP 11.26 billion and trading volume of 5.40 million shares. The same snapshot recorded an average analyst price target of GBX 1,293.33 and a consensus rating of Hold, with three Buy and six Hold ratings among nine analysts.

That target stands GBX 265.83 above the quoted price, a difference of approximately 25.9 percent based on the portal's calculation. The comparison is useful but not a recommendation: the consensus remains Hold, and the target range spans GBX 1,000 to GBX 1,600.

Stock remains below early year level

The September 18 price was also below the GBX 1,238.50 level recorded at the beginning of 2026, leaving the shares 17.0 percent lower on the year according to MarketBeat. The snapshot listed a daily range of GBX 1,025.00 to GBX 1,041.50 and a 50-day range of GBX 1,008.50 to GBX 1,214.50.

For the stock, the tension is clear: the LANDMARK clearance expands the visible product pipeline, while the quoted valuation and analyst split still depend on evidence that new systems can translate into durable procedure growth and earnings.

Smith & Nephew stock stays at GBX 1,027.50

Smith & Nephew stock stood at GBX 1,027.50 on the London Stock Exchange on September 18, 2026, with a daily change of minus 0.77 percent. The quoted market capitalization was GBP 11.26 billion as of the same snapshot.

More news and analyses on Smith & Nephew stock